1,044 results on '"Appella E"'
Search Results
52. Specific DNA binding to a major histocompatibility complex enhancer sequence by a synthetic 57-residue double zinc finger peptide from a human enhancer binding protein
53. The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis
54. Human PMEL17 is sorted to Melanosomes by the adaptor protein complexes 1 and 2.
55. Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35)
56. Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivity
57. Xenoreactive complex AHIII 12.2 TCR bound to p1049/HLA-A2.1
58. Redox-mediated regulation of p21(waf1/cip1) expression involves a post- transcriptional mechanism and activation of the mitogen-activated protein kinase pathway
59. CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDE P1058
60. CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDE P1049-5V
61. The Development of Multi-epitope Vaccines: Epitope Identification, Vaccine Design and Clinical Evaluation
62. Meeting report
63. Characterization of a naturally processed MHC class II-restricted T-cell determinant of hen egg lysozyme
64. Internalization of the urokinase plasminogen activator inhibirot type 1 complex is mediated by the urokinase receptor
65. Structural requirements for the interaction between class II MHC molecules and peptide antigens
66. The human receptor for urokinase plasminogen activator
67. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis
68. Syk-independent tyrosine phosphorylation and association of the protein tyrosine phosphatases SHP-1 and SHP-2 with the high affinity IgE receptor.
69. Determinants of T cell reactivity to the Mycobacterium leprae GroES homologue.
70. Differential contact of disparate class I/peptide complexes as the basis for epitope cross-recognition by a single T cell receptor.
71. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells.
72. Invariant chain and DM edit self-peptide presentation by major histocompatibility complex (MHC) class II molecules.
73. The proteolytic environment involved in MHC class II-restricted antigen presentation can be modulated by the p41 form of invariant chain.
74. Mutational analysis of Lck in CD45-negative T cells: dominant role of tyrosine 394 phosphorylation in kinase activity
75. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35).
76. Autoreactive cytotoxic T lymphocytes in human immunodeficiency virus type 1-infected subjects.
77. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy.
78. Expression of IFN regulatory factor family proteins in lymphocytes. Induction of Stat-1 and IFN consensus sequence binding protein expression by T cell activation.
79. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines.
80. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes.
81. Prominent roles of secondary anchor residues in peptide binding to HLA-A24 human class I molecules.
82. The 37/40-kilodalton autoantigen in insulin-dependent diabetes mellitus is the putative tyrosine phosphatase IA-2.
83. Four p53 DNA-binding domain peptides bind natural p53-response elements and bend the DNA.
84. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes.
85. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes.
86. Multiple point mutations in an endogenous retroviral gene confer high immunogenicity on a drug-treated murine tumor.
87. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
88. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
89. Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II.
90. Constitutive presentation of dominant epitopes from endogenous naturally processed self-beta 2-microglobulin to class II-restricted T cells leads to self-tolerance.
91. Several HLA alleles share overlapping peptide specificities.
92. Constitutive expression of B-myb can bypass p53-induced Waf1/Cip1-mediated G1 arrest.
93. Specific sequences from the carboxyl terminus of human p53 gene product form anti-parallel tetramers in solution.
94. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.
95. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.
96. Molecular interactions between interferon consensus sequence binding protein and members of the interferon regulatory factor family.
97. CD45 regulation of tyrosine phosphorylation and enzyme activity of src family kinases.
98. Definition of a DQ3.1-specific binding motif.
99. Negative selection of CD4+ CD8+ thymocytes by T-cell receptor peptide antagonists.
100. Definition of specific peptide motifs for four major HLA-A alleles.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.